Dublin, Oct. 09, 2017 -- The "Global Active Pharmaceutical Ingredients (API) Market Analysis & Trends - Industry Forecast to 2025" report has been added to Research and Markets' offering.
The Global Active Pharmaceutical Ingredients (API) Market is poised to grow at a CAGR of around 6.6% over the next decade to reach approximately $238.8 billion by 2025.
Some of the prominent trends that the market is witnessing include, Growing Geriatric Population, Rapid growth in biopharmaceuticals sector and Technological Advancements in API Manufacturing.
Based on Therapeutic Area, the market is segregated into oncology, nsaids, neurological disorders, musculoskeletal disorders, cardiovascular disorders, metabolic disorders and other therapeutics uses.
By Drug Type, the market is categorized into OTC prescription drugs, generic prescription drugs and branded prescription drugs. On the basis of Manufacturing Process, the market is segmented into contract manufacturing and captive manufacturing.
Depending on API Type the market is divided into biological API, synthetic chemical API and high potency active pharmaceutical ingredients (HPAPI). The Biological API segment is further categorized into Biotech and Biosimilar. The Synthetic Chemical API segment is further divided into branded/ innovative and generic/non- branded.
This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2014, 2015 revenue estimations are presented for 2016 and forecasts from 2017 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
Report Highlights:
- The report provides a detailed analysis on current and future market trends to identify the investment opportunities
- Market forecasts till 2025, using estimated market values as the base numbers
- Key market trends across the business segments, Regions and Countries
- Key developments and strategies observed in the market
- Market Dynamics such as Drivers, Restraints, Opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2025
- Market opportunities and recommendations for new investments
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Growing Geriatric Population
3.1.2 Rapid growth in biopharmaceuticals sector
3.1.3 Technological Advancements in Api Manufacturing
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
4 Active Pharmaceutical Ingredients (API) Market, By Therapeutic Area
4.1 Oncology
4.2 NSAIDs
4.3 Neurological Disorders
4.4 Musculoskeletal Disorders
4.5 Cardiovascular Disorders
4.6 Metabolic Disorders
4.7 Other Therapeutics Uses
5 Active Pharmaceutical Ingredients (API) Market, By Drug Type
5.1 OTC Prescription Drugs
5.2 Generic Prescription Drugs
5.3 Branded Prescription Drugs
6 Active Pharmaceutical Ingredients (API) Market, By Manufacturing Process
6.1 Contract Manufacturing
6.2 Captive Manufacturing
7 Active Pharmaceutical Ingredients (API) Market, By API Type
7.1 Biological API
7.1.1.1 Biotech
7.1.1.2 Biosimilar
7.2 Synthetic Chemical API
7.2.1.1 Branded/ Innovative
7.2.1.2 Generic/Non- Branded
7.3 High potency active pharmaceutical ingredients(HPAPI)
8 Active Pharmaceutical Ingredients (API) Market, By Geography
9 Key Player Activities
9.1 Acquisitions & Mergers
9.2 Agreements, Partnerships, Collaborations and Joint Ventures
9.3 Product Launch & Expansions
9.4 Other Activities
10 Leading Companies
- Teva Pharmaceutical Industries Limited
- Sun Pharmaceutical Industries Ltd.
- Merial Inc. (Sanofi) (France)
- Merck Animal Health (U.S.)
- Elanco Animal Health (U.S.)
- Dr. Reddy's Laboratories Ltd.
- Ceva Animal Health, Inc.
- Boehringer Ingelheim (Germany)
- Bioniche Animal Health (Canada)
- Aurobindo Pharma Ltd.
- Bayer Healthcare (Germany)
- Heska Co. (U.S.)
- Novartis International AG
- Pfizer, Inc
- Zoetis (U.S.)
- Virbac
- Ranbaxy Laboratories
For more information about this report visit https://www.researchandmarkets.com/research/5jl2gn/global_active
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



